C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
260/468, 260/595
C07C 209/28 (2006.01) C07C 209/70 (2006.01) C07C 211/42 (2006.01) C07C 213/08 (2006.01) C07C 217/74 (2006.01) C07D 223/14 (2006.01)
Patent
CA 1325226
ABSTRACT Biologically active, enantiomerically substantially pure intermediates of trans-hexahydro-benzo[?]naphtho[2,1-b] azepines are prepared. The present invention involves a process for preparing compounds of the general formula 3: Image wherein: R?is Image ; Each R1 is independently H or alkyl; Q is methylene, -O- or-S-; m and n are independently variable and may each have a value of 0, 1 or 2, with the provisos that the sum of m and n is not greater than 3, that m may not equal zero when Q is -O- or -S-, and that when Q is -CH2-, m and n cannot both be zero; X is hydrogen, halo, alkyl, alkylthio, alkylsulfinyl, alkylsufonyl, hydroxy, alkoxy or trifluoromethyl; Y is hydrogen, hydroxy, alkoxy, -OC(O)NR2R3, -OC(O)-R9, - N(R1)2,-NHC(O)R1 or-OP(O)(OH)OR1, R2 and R3 are the same or different and each is hydrogen (provided that both are not hydrogen), alkyl, aralkyl, cycloalkyl, aryl, hydroxyalkyl, or alkoxyalkyl; in addition, when one of R2 and R3 is as defined above, the other may be -R4NR5R6 {wherein R4 is alkanedlyl, R5 is hydrogen or alkyl and R6 is alkyl, or R5 and R6 together with the nitrogen atom form a 1-azetidinyl, 1- pyrrolidinyl, 1-piperidinyl, 1-(4-alkylpiperazinyl), 4-morphollnyl or 1- (hexahydroazepinyl) group}; in further addition, R2 and R3 together with the nitrogen atom may form a 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-(4- alkylpiperazinyl), 1-(4-alkoxyalkylpiperazinyl), 1-(4-hydroxyalkylpiperazinyl),1- (3-hydroxyazetidinyl), 1-(3-alkoxyazetidinyl), 1-(-hydroxypyrrolidinyl), 1-(3- alkoxypyrrolidinyl), 1-(3- or 4-hydroxypiperidinyl), 1-(3- or 4-alkoxypiperidinyl), 1-(4-oxopiperidinyl) or 1-(3-oxopyrrolidinyl) ring; in still further addition, when R2 is hydrogen, R3 may be - CHR7CO2R8, wherein R7 and R8 are the same or different and each is hydrogen, alkyl or aralkyl; R9 is alkyl, aralkyl, aryl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, cycloalkylalkyl, alkoxycarbonylalkyl, cycloalkyl, 1-adamantyl, cycloalkoxyalkyl,alkoxy, aralkyloxy, cycloalkoxy, aryloxy or -CHR7NHR8; and Z is X as defined above, amino, alkylamino or -NHC(O)R10 {wherein R10 is hydrogen, alkyl or aryl). R11 is H or alkyl; R12 is alkyl with the proviso that R11 and R12 are different, and K is hydrogen, alkoxy, hydroxyl, aryloxy or alkyl.
606860
Berger Joel G.
Clader John W.
Berger Joel G.
Clader John W.
Schering Corporation
Swabey Ogilvy Renault
LandOfFree
Process for the enantiospecific synthesis of intermediates... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the enantiospecific synthesis of intermediates..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the enantiospecific synthesis of intermediates... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1279721